297,830 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Bought by Sovereign s Capital Management LLC

Sovereign s Capital Management LLC purchased a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 297,830 shares of the biopharmaceutical company's stock, valued at approximately $2,806,000. Amicus Therapeutics accounts for approximately 1.8% of Sovereign s Capital Management LLC's portfolio, making the stock its 23rd biggest position. Sovereign s Capital Management LLC owned approximately 0.10% of Amicus Therapeutics as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Summit Investment Advisors Inc. increased its position in Amicus Therapeutics by 4.4% in the 4th quarter. Summit Investment Advisors Inc. now owns 30,696 shares of the biopharmaceutical company's stock valued at $289,000 after acquiring an additional 1,280 shares during the period. Xponance Inc. increased its position in Amicus Therapeutics by 11.9% in the 4th quarter. Xponance Inc. now owns 21,216 shares of the biopharmaceutical company's stock valued at $200,000 after acquiring an additional 2,249 shares during the period. Covestor Ltd increased its position in Amicus Therapeutics by 114.9% in the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after acquiring an additional 2,312 shares during the period. Virtus Fund Advisers LLC acquired a new position in Amicus Therapeutics in the 4th quarter valued at approximately $29,000. Finally, KBC Group NV increased its position in Amicus Therapeutics by 44.4% in the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock valued at $96,000 after acquiring an additional 3,120 shares during the period.

Analyst Upgrades and Downgrades

FOLD has been the subject of several recent research reports. Wall Street Zen cut shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. The Goldman Sachs Group reduced their price objective on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research note on Friday, May 2nd. UBS Group upped their price objective on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Finally, Wells Fargo & Company reduced their price objective on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, February 20th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $16.22.

Amicus Therapeutics Stock Down 0.6%

NASDAQ FOLD traded down $0.04 on Friday, hitting $6.22. 2,822,292 shares of the company were exchanged, compared to its average volume of 2,841,418. The company has a market cap of $1.92 billion, a PE ratio of -34.56, a PEG ratio of 1.51 and a beta of 0.64. Amicus Therapeutics, Inc. has a 12 month low of $5.81 and a 12 month high of $12.65. The stock has a fifty day moving average of $7.11 and a 200-day moving average of $8.74. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.